1374831-17-0

Basic information

• Product Name: methyl 3-((N-(2-bromobenzyl)-4-methylphenyl)sulfonamido)thiophene-2-carboxylate
• Synonyms: methyl 3-((N-(2-bromobenzyl)-4-methylphenyl)sulfonamido)thiophene-2-carboxylate
• CAS NO: 1374831-17-0
• Molecular Weight: 480.403
• Mol File: 1374831-17-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 3-((N-(2-bromobenzyl)-4-methylphenyl)sulfonamido)thiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-((N-(2-bromobenzyl)-4-methylphenyl)sulfonamido)thiophene-2-carboxylate(1374831-17-0)
• EPA Substance Registry System: methyl 3-((N-(2-bromobenzyl)-4-methylphenyl)sulfonamido)thiophene-2-carboxylate(1374831-17-0)

Safety Data

• Hazardous Substances Data: 1374831-17-0(Hazardous Substances Data)

Upstream product

• 79128-72-6 methyl 3-((4-methylphenyl)sulfonamido)thiophene-2-carboxylate 
• 3433-80-5 1-Bromo-2-bromomethyl-benzene 
• 98-59-9 p-toluenesulfonyl chloride 
• 100-39-0 benzyl bromide 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 

Downstream Products

• 1374831-24-9 C₂₆H₂₁NO₄S₂ 
• 1374831-26-1 C₂₇H₂₃NO₅S₂ 
• 1374831-38-5 C₂₀H₁₇NO₄S₂ 
• 1374831-40-9 C₂₄H₁₉NO₂S₂ 
• 1374831-42-1 C₂₅H₂₁NO₃S₂ 
• 1374831-45-4 C₂₅H₂₁NO₃S₂ 
• 1374831-46-5 C₂₅H₁₉NO₄S₂ 
• 1374831-47-6 C₂₅H₁₉NO₄S₂ 
• 1374831-52-3 C₃₂H₂₄N₂O₃S₂ 
• 1374831-54-5 C₂₆H₂₁NO₅S₂ 
• 1374831-25-0 C₂₇H₂₃NO₅S₂ 
• 1374831-27-2 C₂₉H₂₅NO₆S₂ 
• 1374831-28-3 C₂₉H₂₅NO₆S₂ 
• 1629164-94-8 C₁₉H₁₆BrNO₄S₂ 

Relevant articles and documents

Design, structure-activity relationship study and biological evaluation of the thieno[3,2-c]isoquinoline scaffold as a potential anti-cancer agent

Several derivatives of a series that share a thienoisoquinoline scaffold have demonstrated potent activity against cancer cell lines A549, HeLa, HCT-116, and MDA-MB-231 in the submicromolar concentration range. Structure-activity relationship (SAR) studies on a range of derivatives aided in identifying key pharmacophores in the lead compound. A series of compounds have been identified as the most promising with submicromolar IC50 values against a lung cancer cell line (A549). Microscopy studies of cancer cells treated with the lead compound revealed that it causes mitotic arrest and disrupts microtubules. Further evaluation via an in vitro microtubule polymerization assay and competition studies indicate that the lead compound binds to tubulin via the colchicine site.